

AmeriCorps. In addition, the survey will collect details about the AmeriCorps experience of members, and employment and educational experiences of individuals in the comparison group in the year after they considered joining, but did not actually join AmeriCorps. Analysis of baseline data collected in the initial round of surveys raised questions about participants' motivations about, and previous involvement in, community service. Data collected in the supplemental survey will allow us to address those concerns.

Type of Review: Revision of a currently approved collection.

Agency: Corporation for National and Community Service.

Title: The Longitudinal Research on Member Outcomes.

OMB Number: #3045-0070.

Agency Number: None.

Affected Public: AmeriCorps members, comparison group individuals.

Total Respondents: 3,337 (1,786 AmeriCorps members; 1,551 Comparison group members).

Frequency: One time.

Average Time Per Response: 45 minutes.

Estimated Total Burden Hours: 2,392 hours.

Total Burden Cost (capital/startup): None.

Total Burden Cost (operating/maintenance): None.

Dated: May 10, 2002.

David A. Reingold,

Director, Department of Research and Policy Development.

[FR Doc. 02-12311 Filed 5-15-02; 8:45 am]

BILLING CODE 6050--\$5-P

DEPARTMENT OF DEFENSE

Department of the Army

Western Hemisphere Institute for Security Cooperation Board of Visitors; Meeting

AGENCY: Department of the Army, DoD.

ACTION: Notice of open meeting.

SUMMARY: This notice sets forth the schedule and summary agenda for the inaugural meeting of the Western Hemisphere Institute for Security Cooperation (WHINSEC) Board of Visitors (BoV). Notice Of this meeting is required under the Federal Advisory Committee Act (Pub. L. 92-463). This board was chartered on February 1, 2002 in compliance with the requirements set forth in 10 U.S.C. 2166.

DATES: June 3-4, 2002.

TIME: 9 a.m. to 12:30 p.m. and 2 p.m. to 5:15 p.m. (June 3, 2002). 9 a.m. to 2 p.m. (June 4, 2002).

LOCATION: Pratt Hall, Building 35, 7011 Morrison Ave., Fort Benning, GA 31905.

PROPOSED AGENDA: The WHINSEC BoV will elect internal leadership, approve its rules or by-laws, establish its annual schedule and review the WHINSEC operations, activities and curriculum for compliance with the authorizing legislation.

FOR FURTHER INFORMATION CONTACT: Ken LaPlante, Core Processes, Inc., Army G-3 (Room 2D337), 400 Army Pentagon, Washington, DC 20310, telephone (703) 692-7419 or LTC Andres Toro at (703) 692-7421.

SUPPLEMENTARY INFORMATION: The meeting is open to the public. There will be time, specified, for public comments by individuals and organizations at the end of the meeting on June 4. Public comment and presentations will be limited to two minutes each and must be provided in writing and received before Friday, May 24, 2002. Mail written presentations and requests to register to attend the public sessions to: LTC Andres Toro, DAMO-SSR (Rm 2D337), 400 Army Pentagon, Washington, DC 20310-0400. Public seating is limited, and is available on a first come, first served basis.

John C. Speedy, III,

SES, Designated Federal Officer, WHINSEC BoV.

[FR Doc. 02-12178 Filed 5-15-02; 8:45 am]

BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Assay for the Proteolytic Activity of Serotype A Neurotoxin From Clostridium Botulinum

AGENCY: Department of the Army, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 5,965,699 entitled "Assay for the Proteolytic Activity of Serotype A Neurotoxin from Clostridium Botulinum" issued October 12, 1999. The United States Government, as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: A label-based assay is described, through modifications of substrate structure and derivatization of serum albumin, which can be used to determine type A proteolytic activity without separation of products.

Luz D. Ortiz,

Army Federal Register Liaison Officer.

[FR Doc. 02-12181 Filed 5-15-02; 8:45 am]

BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Compositions Having Neuroprotective and Analgesic Activity

AGENCY: Department of the Army, DoD.


ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 6,046,200 entitled "Compositions Having Neuroprotective and Analgesic Activity," issued April 4, 2000. The United States Government, as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Compounds of the formula:



wherein R1 and R2 are alkyl of 1–8 carbons have been shown to have both neuroprotective and analgesic activities. The compounds of the invention may be used in treatment of conditions that would normally result in neuronal damage, including those arising on account of cerebral ischemia/hypoxia or increase in intracranial pressure such as neoplasms, stroke, meningitis or trauma. Compositions of the invention can also be useful for treatment of toxin-related damaged such as drug over-dose or exposure to toxins in the environment.

Luz Ortiz,

Army Federal Register Liaison Officer.

[FR Doc. 02–12180 Filed 5–15–02; 8:45 am]

BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Electronic/Automated Information Systems and Methods Which Support the Practice of Medicine

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the following, related U.S. patent applications which all relate to electronic/automated information systems and methods which support the practice of medicine:

U.S. Patent Application No.:

10/038,472.

Filed: January 3, 2002.

Title: Providing for Automated Note Completion.

U.S. Patent Application No.:

10/037,631.

Filed: January 3, 2002.

Title: Providing a Suggested Course of Treatment.

U.S. Patent Application No.:

10/038,567.

Filed: January 3, 2002.

Title: Standardized Inpatient—Outpatient Nomenclatures and Accepting Both Outpatient and Inpatient Data to Commonly Accessible Storage.

U.S. Patent Application No.:

10/037,627.

Filed: January 3, 2002.

Title: Collecting counter signatures.

U.S. Patent Application No.:

10/037,628.

Filed: January 3, 2002.

Title: Providing Outpatient and Inpatient Data Across Outpatient and Inpatient Facilities and Providing Automated Discharge Summary Narration.

The United States Government, as represented by the Secretary of the Army, has rights in these inventions.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034.

SUPPLEMENTARY INFORMATION: The above-identified patent applications all claim the benefit of U.S. Provisional Patent Application No. 60/261,151, filed January 16, 2001, entitled “Standard

Obstetric Record Charting System (STORC); Electronic Obstetric Record.”

Luz D. Ortiz,

Army Federal Register Liaison Officer.

[FR Doc. 02–12185 Filed 5–15–02; 8:45 am]

BILLING CODE 3710–08–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent and Related U.S. Patent Application Concerning Protein Biomarker for Mustard Chemical Injury

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 6,124,108, entitled “Protein Biomarker for Mustard Chemical Injury,” filed May 13, 1997, and related U.S. Patent Application Serial No. 09/482,604, filed January 14, 2000 and having the same title. The United States Government, as represented by the Secretary of the Army has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702–5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619–6664, both at telefax (301) 619–5034.